Literature DB >> 15115750

Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1).

Uwe Karsten1, Nida Serttas, Hans Paulsen, Antje Danielczyk, Steffen Goletz.   

Abstract

Glycosylation determines essential biological functions of epithelial mucins in health and disease. We report on the influence of glycosylation of the immunodominant DTR motif of MUC1 on its antigenicity. Sets of novel glycopeptides were synthesized that enabled us to examine sole and combined effects of peptide length (number of repeats) and O-glycosylation with GalNAc at the DTR motif on the binding patterns of 22 monoclonal antibodies recognizing this motif. In case of unglycosylated peptides almost all antibodies bound better to multiple MUC1 tandem repeats. Glycosylation at the DTR led to enhanced binding in 11 cases, whereas 10 antibodies were not influenced in binding, and one was inhibited. In nine of the former cases both length and DTR glycosylation were additive in their influence on antibody binding, suggesting that both effects are different. Improved binding to the glycosylated DTR motif was exclusively found with antibodies generated against tumor-derived MUC1. Based on these data a tumor-specific MUC1 epitope is defined comprising the ...PDTRP... sequence in a particular conformation essentially determined by O-glycosylation at its threonine with either GalNAcalpha1 or a related short glycan. The results can find application in the field of MUC1-based immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115750     DOI: 10.1093/glycob/cwh090

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  26 in total

1.  MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1.

Authors:  Jennifer J Rahn; Jeffrey W Chow; Garnet J Horne; Brian K Mah; Joanne T Emerman; Pat Hoffman; Judith C Hugh
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  Unraveling the Receptor-Ligand Interactions between Bladder Cancer Cells and the Endothelium Using AFM.

Authors:  Vinoth Sundar Rajan; Valérie M Laurent; Claude Verdier; Alain Duperray
Journal:  Biophys J       Date:  2017-03-28       Impact factor: 4.033

Review 3.  Mucin-based targeted pancreatic cancer therapy.

Authors:  Maria P Torres; Subhankar Chakraborty; Joshua Souchek; Surinder K Batra
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer.

Authors:  Sabine Heublein; Klaus Friese; Bernd Kost; Frederik Marmé; Christina Kuhn; Sven Mahner; Christian Dannecker; Doris Mayr; Udo Jeschke; Aurelia Vattai
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-30       Impact factor: 4.553

Review 5.  Cancer-associated mucins: role in immune modulation and metastasis.

Authors:  Rakesh Bhatia; Shailendra K Gautam; Andrew Cannon; Christopher Thompson; Bradley R Hall; Abhijit Aithal; Kasturi Banerjee; Maneesh Jain; Joyce C Solheim; Sushil Kumar; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2019-06       Impact factor: 9.264

6.  Lipopeptide-Coated Iron Oxide Nanoparticles as Potential Glycoconjugate-Based Synthetic Anticancer Vaccines.

Authors:  Suttipun Sungsuwan; Zhaojun Yin; Xuefei Huang
Journal:  ACS Appl Mater Interfaces       Date:  2015-08-03       Impact factor: 9.229

7.  Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.

Authors:  Vani Lakshminarayanan; Pamela Thompson; Margreet A Wolfert; Therese Buskas; Judy M Bradley; Latha B Pathangey; Cathy S Madsen; Peter A Cohen; Sandra J Gendler; Geert-Jan Boons
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-14       Impact factor: 11.205

8.  Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen.

Authors:  Mohammadreza Movahedin; Teresa M Brooks; Nitin T Supekar; Naveen Gokanapudi; Geert-Jan Boons; Cory L Brooks
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

9.  Preclinical Studies of Granulysin-Based Anti-MUC1-Tn Immunotoxins as a New Antitumoral Treatment.

Authors:  Patricia Guerrero-Ochoa; Raquel Ibáñez-Pérez; Germán Berbegal-Pinilla; Diederich Aguilar; Isabel Marzo; Francisco Corzana; Martha Minjárez-Sáenz; Javier Macías-León; Blanca Conde; Javier Raso; Ramón Hurtado-Guerrero; Alberto Anel
Journal:  Biomedicines       Date:  2022-05-24

10.  Adaptive immune activation: glycosylation does matter.

Authors:  Margreet A Wolfert; Geert-Jan Boons
Journal:  Nat Chem Biol       Date:  2013-12       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.